When should prostate-specific antigen testing be stopped?

February 20, 2009

New York, NY, February 20, 2009 - Although widespread Prostate-Specific-Antigen (PSA) testing has undoubtedly decreased prostate cancer mortality, is there a point of diminishing returns? In a study published in the April 2009 issue of The Journal of Urology, researchers found that in a subgroup of elderly men, among those who were 75 years old or older and had a PSA below 3 ng/ml (nanograms per milliliter), none subsequently died of prostate cancer. The discontinuation of routine PSA screening in these men may not increase the rates of undetected lethal disease, and could avoid potentially unnecessary treatments and reduce diagnostic costs.

Because PSA screening can find cancers that may become life-threatening in 5 to 25 years, there has been increased usage of the test in 40 to 50-year-olds. But the test can also discover cancers that never become life-threatening, perhaps in up to 30% of the cases. Many men who are older than 75 undergo continued PSA screening, potentially leading to unnecessary treatment since death from other causes is more likely than death from prostate cancer.

The study conducted by investigators from the Baltimore Longitudinal Study of Aging (National Institute on Aging, National Institutes of Health) and the Department of Urology at Johns Hopkins School of Medicine involved 849 men (122 with and 727 without prostate cancer) with serial PSA measurements . Researchers found that for men over 75 with PSA < 3ng/ml, none died of prostate cancer and only one developed high-risk prostate cancer. In contrast, men of all ages with a PSA ≥3.0 ng/ml had a continually rising probability of death from prostate cancer.

Writing in the article, Edward M. Schaeffer states, "The optimal approach to prostate cancer screening remains controversial. To date, there is limited evidence from which to inform the decision on when to discontinue prostate cancer screening. Our findings suggest that men at an age of 75-80 years who have a PSA level below 3ng/ml are unlikely to be diagnosed with a high risk prostate cancer during life. These men may therefore represent an ideal target group for discontinuation of PSA testing, which could dramatically reduce the costs associated with screening and the potential morbidity of additional evaluations and/or treatment in a population unlikely to gain benefit." Dr. Schaeffer emphasized that these findings need to be confirmed in a much larger study, and that men over the age of 75 years should continue to be monitored for development of clinical signs of prostate cancer.
-end-
The article is "Prostate Specific Antigen Testing Among the Elderly: When To Stop?" by Edward M. Schaeffer MD, PhD, H. Ballentine Carter MD, Anna Kettermann MA, Stacy Loeb MD, Luigi Ferrucci MD, PhD, Patricia Landis BS, Bruce J. Trock PhD, and E. Jeffrey Metter MD. It appears in The Journal of Urology, Volume 181, Issue 4 (April 2009) published by Elsevier.

Elsevier Health Sciences

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.